OGEN - יחס חוב להיוון בספרים oragenics.com

Oragenics, Inc. logistics are based on a strict temperature-controlled delivery regime for antibiotics to clinics. Simultaneously, Oragenics, Inc. is developing peptide therapies for brain injury rehabilitation at the preclinical stage. The strategy aims for the expansion of the drug ONP-002 to capture the infection market. This financial leverage chart based on balance sheet capitalization demonstrates the stability of the asset structure, where the current parameter equals 0.00.

Investors must evaluate the financial autonomy of Oragenics, Inc. (OGEN) to determine the asset's long-term sustainability. This ratio measures the proportion of debt obligations within the equity structure, defining the business's degree of dependence on external financing. Analyzing the ratio of borrowed funds to book capitalization allows for the tracking of excessive leverage risk. A decrease in this metric confirms the company's solvency, which is critically important when implementing costly antibiotic developments in collaboration with government centers.